TOKYO, March 14, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma provided updates during its FY2022 financial results disclosure on March 13, including positive topline results of two phase III clinical trials, in moderate to severe atopic dermatitis (ARCADIA 1 and ARCADIA 2) for the humanized anti-human IL-31 receptor A monoclonal antibody nemolizumab, created by Chugai.

The two-phase III clinical trials, ARCADIA 1 and ARCADIA 2, in moderate to severe atopic dermatitis confirmed that nemolizumab in combination with topical therapy met all co-primary endpoints and key secondary endpoints, and improved skin lesions, pruritus, and sleep disturbance. Galderma plans to present the results from these two trials to the scientific community at a congress later in 2023 and is on track to launch in the U.S. in the second half of 2024.

In addition, new information was announced on the phase III studies OLYMPIA 1 and OLYMPIA 2 in prurigo nodularis. OLYMPIA 2 study met all of its primary endpoints and key secondary endpoints.¹ Galderma is on track to receive the results from its second clinical trial in prurigo nodularis, OLYMPIA 1, and plans to launch in the U.S. in the second half of 2024.

Please refer to the link below for details:

Galderma delivers strong FY 2022 growth driven by innovation and commercial performance
https://www.galderma.com/news/galderma-delivers-strong-fy-2022-growth-driven-innovation-and-commercial-performance

[Reference Information]

1. Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo Nodularis (Press Release on June 22, 2022) https://www.chugai-pharm.co.jp/english/news/detail/20220622160000_930.html